Article info
PDFShort Report
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- ↵a 240-760-6132 alexandra.zimmer{at}nih.gov
- ↵b erin.nichols{at}nih.gov
- ↵c acimino1{at}jhmi.edu
- ↵d cody.peer{at}nih.gov
- ↵e caoli{at}mail.nih.gov
- ↵f min-jung.lee{at}nih.gov
- ↵g kohne{at}mail.nih.gov
- ↵h annunzic{at}mail.nih.gov
- ↵i lipkowis{at}navmed.nci.nih.gov
- ↵j trepelj{at}mail.nih.gov
- ↵k rsharma{at}jhmi.edu
- ↵l lekha.mikkilineni{at}nih.gov
- ↵m margaret.gatti-mays{at}nih.gov
- ↵n figgw{at}mail.nih.gov
- ↵o houstonnd{at}mail.nih.gov
- ↵p leej6{at}mail.nih.gov
Citation
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Publication history
- Received May 6, 2019
- Accepted July 16, 2019
- First published July 25, 2019.
Online issue publication
January 08, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.